X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA), was shown to induce immunity against PSCA and significantly augmented T-Cell responses.
Lead Product(s): VTX-0P4
Therapeutic Area: Oncology Product Name: VTX-0P4
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Under the terms of the agreement, Harvard Medical School will initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.
Lead Product(s): Undislcosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 28, 2023
Details:
VaxCelerate: the Use of MTBhsp70-Avidin as an Adjuvant to Create Self-Assembling Vaccines for Emerging Infectious Diseases Vaccine and Immunotherapy Center.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
VTX-067, a Self-Assembling Vaccine (SAV) targeting select peptides from HPV related cancers, was developed using Voltron's Self Assembling Vaccine Platform.
Lead Product(s): VTX-067
Therapeutic Area: Oncology Product Name: VTX-067
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Massachusetts General Hospital's Vaccine and Immunotherapy Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
Initiation of this study was the culmination of a tremendous effort by our highly skilled team of scientists, physicians and manufacturing experts to design and manufacture VTX-067 to bolster the immune system against a validated oncology target.
Lead Product(s): VTX-067
Therapeutic Area: Oncology Product Name: VTX-067
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Lucius Partners
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
